GNRH1 and prostate cancer: Like for radiation therapy, the neoadjuvant or adjuvant use of hormone manipulation has not been completely evaluated, apart from an experience of Ficarra[19] who proposed a 3-year hormonal therapy with LH-RH blockade in the setting of high risk prostate cancer according to D'Amico risk classification, or the experimental findings of Paparel[37] with the use in a rat model of the synergic positive effects of HIFU and docetaxel.